AI and Automation Could Mean Big Dough for Domino’s

Six months later, its AI discovered a new treatment for multiple myeloma. Unsubscribe A Message from Behind the Markets Dear Fellow Investor, In April 2021, NIVIDIA partnered with a tiny biotech to help power its AI-drug discovery platform. Six months later, its AI discovered a new treatment for multiple myeloma. Six months after that, Eli Lilly signed a $425 million deal to have them develop new drugs. Six months after that, Bristol Myers Squibb signed a $2.7 billion deal to have its AI-platform develop new drugs. That's why Bill Gates, BlackRock and Morgan Stanley own 16 million shares of this "little-known" company. Get the name of this small-cap here >>> "The Buck Stops Here,"

This message is a paid advertisement sent on behalf of Behind the Markets, a third-party advertiser of MarketBeat. Why did I receive this email?   If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 326 E 8th St #105, Sioux Falls, SD 57103. United States.   Today's Bonus Content: This is the #1 Stock to Buy for the AI Tidal Wave